Back to Journals » OncoTargets and Therapy » Volume 10

Letter to the editor regarding "Prognostic role of microRNA-150 in various carcinomas: a meta-analysis"

Authors Li M, Yang Y

Received 20 November 2016

Accepted for publication 30 November 2016

Published 13 January 2017 Volume 2017:10 Pages 361—362

DOI https://doi.org/10.2147/OTT.S128240

Checked for plagiarism Yes

Editor who approved publication: Dr Samir Farghaly

Min Li,1 Ying Yang2

1Department of Oncology, Changsha Central Hospital, Changsha, Hunan, 2Department of Orthopaedic Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

Emerging evidence has shown that aberrant microRNA expression has the potential to be used for predicting survival and treatment response of carcinomas.1–3 Recently, the role of miR-150 was investigated in various types of cancers, but the results were inconsistent and inconclusive.4–7 Therefore, we read with great interest the enlightening work of Wang et al8 published in OncoTargets and Therapy. This study conducted a meta-analysis to evaluate the prognostic significance of miR-150 in various carcinomas by calculating the pooled hazard ratio (HR) of both overall survival (OS) and progression-free survival (PFS) in patients with various types of cancer. The authors concluded that miR-150 expression was not significantly associated with multiple cancers in terms of OS, whereas the high expression of miR-150 was significantly associated with worse progression. It is a very interesting and valuable study. Before accepting their conclusions, we would like to express some concerns in relation to their meta-analysis.

View the original paper by Wang et al.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author: